Background: The risk of recurrence following ischemic stroke or transient ischemic attack is highest immediately after the event. Antiplatelet agents are effective in reducing the risk of recurrence and two agents are superior to one in the early phase after ictus.
Introduction
The risk of recurrence following an ischemic stroke (IS) or transient ischemic attack (TIA) is very high over the first hours and days after the event, 1,2 reaching up to $10% by 90 days and then declining, with a total of about 40% by five years. Typically, recurrent events are more severe than index events and thus increased dependency, disability, cognitive impairment and dementia, poor quality of life, and institutionalization are all more likely. 3, 4 The long-term risk of recurrence can be reduced through lifestyle changes (smoking cessation and reducing weight, salt, saturated fat, and high alcohol intake) and proven, cost-effective pharmacological (antihypertensives and statins) and surgical interventions (carotid endarterectomy or stenting in large vessel disease). [1] [2] [3] [4] [5] [6] [7] [8] Oral anticoagulation is established for patients following cardioembolic stroke [9] [10] [11] [12] while the majority of patients with non-cardioembolic ischemic events (stroke and TIA) require antiplatelet therapy. [13] [14] [15] [16] [17] [18] [19] [20] In long-term secondary stroke prevention, dual antiplatelet therapy with aspirin and dipyridamole reduced recurrent events by 23% as compared with either aspirin or dipyridamole in isolation, and without increasing bleeding risk. 17, 19 However, the combination of aspirin and clopidogrel given chronically was not superior to either drug alone, and dual therapy resulted in increased bleeding as compared with clopidogrel alone. [21] [22] [23] In contrast, more intensive antiplatelet therapy may give improved prophylaxis in the acute phase of stroke or TIA. While early antiplatelet therapy with aspirin following acute IS is effective at reducing early recurrence, 15, 16, 24 dual antiplatelet therapy started within 72 h of onset reduced early recurrence risk more than monotherapy in a meta-analysis of small studies. 25 Moreover, the type of agents used was less important than using dual rather than monotherapy. This was supported by the findings of the large CHANCE trial; dual antiplatelet therapy with aspirin and clopidogrel was superior to aspirin alone in preventing stroke recurrence by 90 days when commenced within 24 h of minor IS or TIA. 26, 27 One potential benefit of using multi-antiplatelet agents is the mitigation of treatment resistance seen individually with aspirin and clopidogrel monotherapy. [28] [29] [30] If dual antiplatelet therapy reduces stroke recurrence following acute IS or TIA as compared to monotherapy, then triple/intensive antiplatelet therapy with combined aspirin, clopidogrel, and dipyridamole might be even more effective, providing the risk of recurrence is high and bleeding is not excessive. Several laboratory studies and clinical trials have assessed this concept. [31] [32] [33] [34] [35] Triple therapy in vitro was most effective in inhibiting leucocyte activation, platelet-leucocyte conjugation, and platelet aggregation. [31] [32] [33] Phase I and II multiway crossover trials compared short-term administration of single, dual, and triple antiplatelets and found that aspirin and clopidogrel, with or without dipyridamole, were most effective at inhibiting platelet function in healthy volunteers and those with previous stroke or TIA. 34, 35 A parallel group trial comparing long-term triple antiplatelet therapy with aspirin alone in participants with stroke found that intensive treatment was feasible to administer for up to 24 months, but there was a non-significant trend to increased bleeding. 36 In addition, chronic use of triple antiplatelet therapy in patients with a very high risk of recurrence following events on dual therapy appeared to be effective in minimizing further events without increasing bleeding. 37 Based on these preclinical and clinical data showing feasibility, tolerability, apparent safety and potential efficacy for triple antiplatelet therapy, the triple antiplatelets for reducing dependency after ischemic stroke (TARDIS) trial tested the overall safety and efficacy of short-term intensive antiplatelet therapy in comparison with guideline treatment. The protocol and statistical analysis plan have been published previously. 38, 39 Methods
Eligibility and consent
The full inclusion and exclusion criteria are published 38 and listed in the latest version of the protocol (online Appendix A, B). Adults aged >50 years with noncardioembolic TIA or stroke within 48 h of onset were eligible. Those whose index event was a TIA had:
. Resolved limb weakness and/or dysphasia. . Symptom duration between 10 min and 24 h.
International Journal of Stroke, 12 (5) . ABCD2 score 40 >4; and/or crescendo TIA; and/or already on dual antiplatelet therapy. IS participants had: . Ongoing limb weakness, or ongoing facial weakness with resolved limb weakness; and/or dysphasia; and/ or ongoing isolated hemianopia (with positive neuroimaging of ischemia affecting the corresponding occipital lobe); and duration >1 h. . Resolved limb weakness; and/or dysphasia; with duration >24 h after onset (i.e. resolution between 24 h and randomization). . Note: Any severity of stroke could be recruited.
Patients gave written informed consent prior to enrolment; if they lacked capacity (e.g. due to dysphasia, confusion, or reduced conscious level) then proxy consent could be obtained from a relative, carer, or legal representative, and if not available then independent physician proxy consent was permitted. Neuroimaging was essential for IS to exclude intracranial hemorrhage and a non-stroke diagnosis. Patients who were thrombolyzed for stroke were eligible for inclusion following a delay of 24 h and providing neuroimaging excluded secondary intracranial hemorrhage. Neuroimaging was performed in patients presenting with a TIA at the discretion of local clinicians.
Randomization and data collection
After obtaining informed consent, the local investigator used a secure password-protected and data-encrypted web-based randomization system to enter a participant into the trial (a system derived from that used in the ENOS trial 41 ). The system recorded baseline characteristics following validation of data using range and consistency checks, and then allocated the participant to a treatment group. To achieve optimal baseline matching between treatment groups and ensure concealment of allocation, randomization incorporated stratification (country, index event: stroke or TIA) and minimization (on baseline prognostic factors and additional criteria for TIA and stroke respectively, as highlighted in Tables 2 and 3) ; the minimization algorithm included a random element (simple randomization) in 5% of patients. Stratification and minimization allow for improved matching at baseline, stratification allows variable categories to be treated as trials in their own right, minimization increases statistical power, 42 and simple randomization reduces predictability. Following randomization, the local investigator was informed of the patient's treatment allocation to triple/intensive or guideline antiplatelet therapy; randomized treatment was taken for one month, after which participants on intensive antiplatelet therapy reverted to guideline therapy. The minimization variables will be used for adjustment of the primary and secondary analyses in the main publication, 39 as recommended. 42 
Investigational medicinal products
Trial interventions were given open label for one month (28 or 30 days depending on treatment pack size), a period chosen to cover the period of maximum risk of recurrence but minimize bleeding, and comprised:
. Aspirin: loading dose 300 mg then 50-150 mg daily; by oral, nasogastric tube (NGT) or rectal route. . Clopidogrel: loading dose 300 mg then 75 mg daily;
by oral or NGT route. . Dipyridamole: 225-450 mg in divided doses; by oral (as 200 mg extended release capsules twice daily, or as 25-100 mg tablets three to four times daily) or NGT (as suspension or crushed tablets three to four times daily) route. Participants were randomized to either: . Intensive/triple antiplatelets (active): Combined aspirin, clopidogrel, and dipyridamole. . Guideline/dual or mono antiplatelet(s): Combined aspirin and dipyridamole, or clopidogrel alone.
Throughout the trial, five protocol amendments were made covering multiple issues. The main change concerned an update of guidelines relating to antiplatelet agents after stroke. When the trial commenced, the National Institute for Health and Clinical Excellence (NICE) recommended aspirin and dipyridamole for secondary prevention, 43 which the initial protocol defined as guideline therapy. However, significant randomized evidence supporting the use of clopidogrel for secondary stroke prophylaxis, and widespread availability of generic inexpensive clopidogrel, resulted in NICE updating their guidance in 2010, this recommending that clopidogrel should be used first-line after non-cardioembolic IS. 44 Therefore, the trial protocol was updated allowing for use of either aspirin and dipyridamole, or clopidogrel monotherapy, as the guideline comparator (online Appendix C). Local investigators were able to choose whether randomization included either or both comparators, and this decision was made separately for stroke and TIA. made that the patient was still alive, either via the general practitioner or using electronic records; the patient and/or carer was then contacted by telephone. Where telephone contact could not be made, outcome information was collected using a postal questionnaire. The primary outcome was the occurrence and severity of recurrent stroke and TIA, with severity measured using a six-level ordered categorical scale incorporating the modified Rankin Scale (mRS 45 ): fatal stroke/severe non-fatal stroke (mRS 4 or 5)/ moderate stroke (mRS 2 or 3)/mild stroke (mRS 0 or 1)/TIA/no stroke or TIA. Recurrent events and mRS were determined centrally by telephone by a trained assessor masked to treatment at day 90. Local investigators assessed and reported secondary, bleeding, and safety outcomes (including death) at days 7 and 35, and at hospital discharge (if admitted). Secondary outcomes were also collected at day 90, including bleeding, death, and measures of disability, cognition, mood, and quality of life. 38 
Use of the internet
The TARDIS trial used the internet to randomize and collect data in real-time on line:
. 
Funding and governance
The TARDIS trial received two phases of funding:
. 38 The trial was supervised by a Trial Steering Committee, with support from an International Advisory Committee; run by a Trial Management Committee (part of Nottingham Stroke Trials Unit); and monitored by an independent Data Monitoring Committee (DMC). The DMC met and assessed safety and efficacy on 13 occasions during the trial; prior to 2016, they recommended that the trial should continue with recruitment with no change to the protocol. Independent experts adjudicated brain scans and serious adverse events, blinded to treatment.
Results

Trial delivery
Recruitment progressed with a start-up phase in a limited number of sites, and then expanded to a main phase (Figure 1 ). During the trial's progress, a number of logistical issues arose (online Appendix C). The DMC recommended in March 2016 that the trial should stop recruitment; the TSC reviewed the same data and agreed to stop recruitment, complete followups, and close the trial once data had been validated, the database locked and analyzed, and all sites closed. An explanation to the trial's early stopping will be provided in the main publication.
Baseline characteristics
The following data are given as number (%) or mean (standard deviation); 3096 participants were recruited between April 2009 and March 2016 from 106 sites (online Appendix D) across four countries in two continents: Denmark 51 (1.6%), Georgia 83 (2.7%), New Zealand 7 (0.2%), and UK 2955 (95.4%) ( Table  1) . Four sites recruited a high number of participants relative to other sites ( Figure 2 ).
The baseline characteristics at the time of randomization are presented in Tables 2 and 3 . Key features include: age 69.0 (10.1) years; male 1945 (62.8%); time from onset to recruitment 29.4 (11.9) h (Figure 3(a) ); severity (National Institutes of Health Stroke Scale, NIHSS) 2.8 (3.6); mean blood pressure 143.5 (18.2)/ 79.5 (11.4) mmHg; IS 2143 (69.2%), TIA 953 (30.8%). In comparison with patients whose randomizing event was stroke, patients with TIA were more likely to have pre-morbid hypertension, hyperlipidemia, and a shorter time to randomization (Figure 3(b) and (c)), but were less likely to be current smokers. Table 4 shows univariate relationships between several key baseline factors, including year of randomization into the trial. As the trial progressed, average NIHSS and ABCD2 scores, systolic blood pressure, time to randomization, and proportion of strokes (versus TIA) increased. Further, increasing time to randomization was associated with increased NIHSS score, stroke rather than TIA, and lower SBP; higher SBP was associated with increasing age, NIHSS, and ABCD2 scores; those with strokes were younger; and
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Reporting of results
Following completion of data validation, the database will be locked and the trial unblinded and analyzed. It is intended to present the main results in late 2016/early 2017, with the main manuscript published in parallel.
Multiple pre-specified secondary publications and analyses are described in the statistical analysis plan. 39 TARDIS data will be shared with prospective individual patient data meta-analyses:
. Antiplatelet agents in acute stroke/TIA. . Virtual international stroke trials archive (VISTA). 46 Ultimately, a subset of data will be made available on the internet akin to the International Stroke Trial, 47 and anonymized neuroimaging data will be published. 48 
Discussion
TARDIS is the first trial to assess the safety and efficacy of intensive antiplatelet therapy based on three agents in comparison with guideline treatment; with 3096 patients, TARDIS is a large international trial. The characteristics of the participants justify several comments. First, although the trial was designed to run internationally, contracting issues, largely related to national sponsorship and availability of insurance (online Appendix C), led the trial to recruit predominantly a UK-population; with a large number of recruiting sites, it is therefore representative primarily of UK stroke services and their patients; however, participants also came from three other countries with predominantly Caucasian populations. Second, the proportion of International Journal of Stroke, 12(5) stroke patients recruited as compared with TIAs was higher than intended; the proportion of stroke increased as the trial progressed, probably related to closure of other large stroke trials such as ENOS and SO 2 S. 41, 49 Third, in addition to more stroke patients being recruited over time, their severity, SBP, and time to randomization also increased, this reflecting differences in the types of participants recruited by sites who joined the trial later. Last, TIA patients were recruited much earlier than those with stroke as their index event, which may have implications for both efficacy and risk. Although TARDIS is large, and definitive and significant results may help drive changes in clinical practice, it will still be necessary to merge individual patient data from TARDIS with other large trials of antiplatelet agents in acute IS and TIA to fully assess their effects in different patient subgroups. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The TARDIS start-up phase was funded by the British Heart Foundation (grant PG/08/083/25779, 1 April Table 4 . 
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